Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis
Open Access
- 11 March 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 60 (1), 334-348
- https://doi.org/10.1002/hep.27117
Abstract
Activation of the renin angiotensin system resulting in stimulation of angiotensin-II (AngII) type I receptor (AT1R) is an important factor in the development of liver fibrosis. Here, we investigated the role of Janus kinase 2 (JAK2) as a newly described intracellular effector of AT1R in mediating liver fibrosis. Fibrotic liver samples from rodents and humans were compared to respective controls. Transcription, protein expression, activation, and localization of JAK2 and downstream effectors were analyzed by real-time polymerase chain reaction, western blotting, immunohistochemistry, and confocal microscopy. Experimental fibrosis was induced by bile duct ligation (BDL), CCl4 intoxication, thioacetamide intoxication or continuous AngII infusion. JAK2 was inhibited by AG490. In vitro experiments were performed with primary rodent hepatic stellate cells (HSCs), Kupffer cells (KCs), and hepatocytes as well as primary human and human-derived LX2 cells. JAK2 expression and activity were increased in experimental rodent and human liver fibrosis, specifically in myofibroblastic HSCs. AT1R stimulation in wild-type animals led to activation of HSCs and fibrosis in vivo through phosphorylation of JAK2 and subsequent RhoA/Rho-kinase activation. These effects were prevented in AT1R−/− mice. Pharmacological inhibition of JAK2 attenuated liver fibrosis in rodent fibrosis models. In vitro, JAK2 and downstream effectors showed increased expression and activation in activated HSCs, when compared to quiescent HSCs, KCs, and hepatocytes isolated from rodents. In primary human and LX2 cells, AG490 blocked AngII-induced profibrotic gene expression. Overexpression of JAK2 led to increased profibrotic gene expression in LX2 cells, which was blocked by AG490. Conclusion: Our study substantiates the important cell-intrinsic role of JAK2 in HSCs for development of liver fibrosis. Inhibition of JAK2 might therefore offer a promising therapy for liver fibrosis. (Hepatology 2014;60:334–348)Keywords
This publication has 47 references indexed in Scilit:
- Hepatocyte-specific Deletion of Janus Kinase 2 (JAK2) Protects against Diet-induced Steatohepatitis and Glucose IntoleranceJournal of Biological Chemistry, 2012
- IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinomaMolecular Cancer, 2011
- Angiotensin signalling in pulmonary fibrosisThe International Journal of Biochemistry & Cell Biology, 2011
- Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2JCI Insight, 2011
- Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current statusBritish Journal of Pharmacology, 2010
- Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosisFibrogenesis & Tissue Repair, 2010
- Myeloperoxidase acts as a profibrotic mediator of atrial fibrillationNature Medicine, 2010
- Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusionLiver Transplantation, 2010
- Platelet-Derived Growth Factor Signaling Through Ephrin-B2 Regulates Hepatic Vascular Structure and FunctionGastroenterology, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008